DEVELOPMENTAL PROJECTS PROGRAM I. INTRODUCTION The goals of the Developmental Project Program of the Skin Cancer SPORE are 1) to provide short-term funding for innovative and meritorious research projects in skin cancer research that have the potential to evolve into translational studies across the Dana Farber Harvard Cancer Center (DFHCC) and, more broadly, the Harvard medical community, and 2) to ensure a continuous supply of high quality and innovative translational research to complement existing and new projects in the Skin Cancer SPORE. These projects may be investigator initiated laboratory or clinical research, or they might be designed to create a shared resource or enhance the research infrastructure of the SPORE. The Developmental Project Program will rely on the infrastructure created by the Administrative Core (Core 1) to accomplish these goals. The process will involve: 1) Identification of promising areas of translational research related to skin cancer 2) Solicitation of high quality applications addressing these and other areas 3) Selection of worthy Projects for funding 4) Provision of funds to the Projects 5) Evaluation of progress and accomplishments of the Projects including the possibility of transition into full Project status 6) Evaluation of the success of the Developmental Program as a whole This process has served us well, and three new full projects in this competitive renewal (Projects 3,4, and 5) are based upon scientific results that emerged from developmental projects. Similar processes are currently in place and working well for the other DFHCC SPOREs. The specific steps in this process are described in more detail below.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA093683-10
Application #
8380226
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2014-01-31
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
10
Fiscal Year
2012
Total Cost
$37,972
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
de Masson, Adele; O'Malley, John T; Elco, Christopher P et al. (2018) High-throughput sequencing of the T cell receptor ? gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med 10:
Sung, Hyeran; Kanchi, Krishna L; Wang, Xue et al. (2016) Inactivation of RASA1 promotes melanoma tumorigenesis via R-Ras activation. Oncotarget 7:23885-96
Yazawa, Erika M; Geddes-Sweeney, Jenna E; Cedeno-Laurent, Filiberto et al. (2015) Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential. J Invest Dermatol 135:1849-1862
Litvinov, Ivan V; Netchiporouk, Elena; Cordeiro, Brendan et al. (2015) The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL). Clin Cancer Res 21:2820-9
Kirsch, Ilan R; Watanabe, Rei; O'Malley, John T et al. (2015) TCR sequencing facilitates diagnosis and identifies mature T cells as the cell of origin in CTCL. Sci Transl Med 7:308ra158
Lee, Jonathan J; Granter, Scott R; Laga, Alvaro C et al. (2015) 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies. Mod Pathol 28:218-29
Ma, Jie; Frank, Markus H (2015) Isolation of Circulating Melanoma Cells. Methods Mol Biol :
Jain, Salvia; Stroopinsky, Dina; Yin, Li et al. (2015) Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood 126:354-62
Watanabe, Rei; Gehad, Ahmed; Yang, Chao et al. (2015) Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med 7:279ra39
Lee, Jonathan J; Cook, Martin; Mihm, Martin C et al. (2015) Loss of the epigenetic mark, 5-Hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma. Oncotarget 6:37995-8004

Showing the most recent 10 out of 132 publications